Select Transactions
March 2024
![]() |
Has been acquired by Innovaccer
Exclusive financial advisor
Pharmacy Quality Solutions
Has been acquired by Innovaccer
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to Pharmacy Quality Solutions (PQS), a leading pharmacy-payer performance technology, in its sale to Innovaccer.
![](https://www.firstanalysis.com/webfiles/PQS_tl_21032024224432.png)
About Pharmacy Quality Solutions:
Pharmacy Quality Solutions (PQS) aligns healthcare payers and pharmacies to achieve their shared goals of better patient outcomes and healthcare quality performance. As a neutral, trusted intermediary supporting the evolution of value-based care, PQS facilitates nationwide pharmacy-based care through its partners and the EQUIPP platform. Using deep clinical pharmacy knowledge and over a decade of performance management experience, PQS helps clients develop strategies, implement quality improvement programs and optimize the quality of healthcare for their Medicare, Medicaid and commercial populations.
![](https://www.firstanalysis.com/webfiles/Innovaccer_bl_21032024224432.png)
About Innovaccer:
Innovaccer is the data platform that accelerates care innovation through innovative AI technologies. Innovaccer’s AI-powered healthcare platform unifies patient data across systems and care settings and empowers healthcare organizations with scalable, modern applications that improve clinical, financial, operational and experiential outcomes. Innovaccer’s EHR-agnostic solutions have been deployed across more than 1,600 hospitals and clinics in the U.S., enabling care delivery transformation for more than 96,000 clinicians and helping providers work collaboratively with payers and life sciences companies. Innovaccer has helped its customers unify health records for more than 54 million people and generate over $1.5 billion in cumulative cost savings. The Innovaccer platform is an industry-leading data and analytics platform, the Best in KLAS CRM solution, and the No. 1 rated population health technology platform by Black Book.
February 2024
![]() |
Has partnered with ReviveHealth and Eir Partners
Exclusive financial advisor
BHS
Has partnered with ReviveHealth and Eir Partners
Exclusive financial advisor
First Analysis focuses its advisory services on high-growth, entrepreneur-driven companies like BHS. The First Analysis team worked closely with the founder and management team to optimally position the company and find the best partner to help BHS to continue to achieve its objectives. First Analysis was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
![](https://www.firstanalysis.com/webfiles/BHSLogo_tl_12032024094940.png)
About BHS:
As a trusted provider of high-touch mental health and well-being solutions, BHS is focused on bettering lives and driving desired outcomes for its customers. With over 40 years of experience, BHS has provided long-standing, comprehensive programs to employers and their employees, higher education institutions and their students, unions/associations and their members, healthcare systems and their patients and communities and their residents. Since its inception, BHS has been committed to providing high-quality clinician-led experiences, as evidence proves that a human-to-human approach leads to better participant results and more substantial customer outcomes. BHS is dedicated to guiding individuals to the right resources at the right time and enhancing their health, productivity, and safety while simultaneously improving the culture, performance, and profitability of the organizations it serves. Helping people and organizations is BHS’s priority and passion.
September 2023
![]() |
Has been acquired by Gemspring
Exclusive financial advisor
ClearCompany
Has been acquired by Gemspring
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to ClearCompany, a full-spectrum talent management platform, in Gemspring Capital’s acquisition of the company.
![](https://www.firstanalysis.com/webfiles/clearcompany_tl_27092023100532.png)
About ClearCompany:
ClearCompany, a full-spectrum talent management platform, has enabled thousands of companies to maximize talent by empowering people at every stage of the employee journey. ClearCompany integrates data-driven best practices, expert-informed content and tailored software tools to recruit, ramp, recognize and retain employees, uniting people and processes to achieve business success.
![](https://www.firstanalysis.com/webfiles/Gemspring_2_bl_27092023100532.png)
About Gemspring:
Gemspring Capital, a Westport, Conn.-based private equity firm with $3.5 billion of capital under management, provides flexible capital solutions to middle market companies. Gemspring partners with talented management teams and takes a partnership approach to helping drive revenue growth, value creation and sustainable competitive advantages. Target companies have up to $500 million in revenue in the aerospace and defense, business services, consumer, financial and insurance services, healthcare services, industrial services, software and tech-enabled services or specialty manufacturing sectors.
March 2023
![]() |
Growth equity investment by FTV Capital
Exclusive financial advisor
$43,000,000
Masttro
$43,000,000
Growth equity investment by FTV Capital
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to Masttro in its $43 million growth equity investment led by FTV Capital. First Analysis focuses its advisory services on high-growth, entrepreneur-driven software companies like Masttro. The First Analysis team worked closely with the founder and management team to optimally position the Company and find the best partner to help Masttro to continue to achieve its objectives. First Analysis was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
![](https://www.firstanalysis.com/webfiles/Masttro_tl_10032023081500.png)
About Masttro:
Masttro is a leading wealth tech platform that enables a 360-degree view of wealth. The platform provides a single source of accurate data to give wealth owners and their trusted advisors ultimate control, transparency, and peace of mind to make informed, data-driven decisions in real-time. Masttro offers a total wealth overview covering all illiquid and liquid investments including passion assets. It comes with a comprehensive suite of features including direct data aggregation and AI-driven document data extraction to construct the basis for powerful interactive real-time analysis and reporting needs – all protected by best-in-class cybersecurity architecture and data security protocols.
![](https://www.firstanalysis.com/webfiles/FTV Capital_bl_10032023081500.png)
About FTV Capital:
FTV Capital is a sector-focused growth equity investment firm that has raised $6.2 billion to invest in high-growth companies offering a range of innovative solutions in three sectors: enterprise technology and services, financial services, and payments and transaction processing. FTV’s experienced team leverages its domain expertise and proven track record in each of these sectors to help motivated management teams accelerate growth.
January 2023
![]() |
Has received investment from QHP Capital
Exclusive financial advisor
COPILOT
Has received investment from QHP Capital
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to COPILOT Provider Support Services, LLC, in QHP Capital’s investment in the company.First Analysis focuses its advisory services on high-growth, entrepreneur-driven companies like COPILOT. The First Analysis team worked closely with the co-founders and management team to optimally position the company and find the best partner to help COPILOT to continue to achieve its objectives.
![](https://www.firstanalysis.com/webfiles/CoPilot_tl_10012023092148.png)
About COPILOT:
COPILOT is a digital-first patient-centric reimbursement hub services platform intended to support the relationship between patients, health care providers and pharmaceutical and device manufacturers.
![](https://www.firstanalysis.com/webfiles/QHP Capital_bl_10012023092148.png)
About QHP Capital:
QHP Capital is an investor in technology and services companies in the life sciences and healthcare sectors. QHP Capital spun out of NovaQuest Capital Management, which was formed in 2000 with the vision of building an investment platform to provide strategic capital and industry expertise in partnership with strong management teams.
January 2023
![]() |
Has acquired Picwell
Exclusive buy-side financial advisor
Jellyvision
Has acquired Picwell
Exclusive buy-side financial advisor
First Analysis acted as the exclusive buy-side financial advisor to Jellyvision, a leading employee benefits engagement solution provider, in its acquisition of Picwell, a healthcare technology company focused on AI-generated benefits decision support.
![](https://www.firstanalysis.com/webfiles/Jellyvision_tl_17012023103013.png)
About Jellyvision:
Jellyvision's mission is to improve lives by helping people choose and use their benefits. The company's platform, ALEX, provides employees with 24/7 benefits resources and guidance at key moments when they're already thinking about their health and well-being. Through behavioral science, Jellyvision engages employees in a benefits experience that leads to smarter decision-making, more money saved, and increased trust in their employer.
![](https://www.firstanalysis.com/webfiles/Picwell_bl_17012023103013.png)
About Picwell:
Picwell is a healthcare technology company providing enterprise solutions to enhance health insurance and employee benefits and improve consumer experiences. Its flagship offering, Picwell DX, is a SaaS-based decision support product that uses artificial intelligence to match individuals to the right health benefits during enrollment by predicting future care considerations, estimating out-of-pocket expenses, and accounting for individual preferences. Other solutions support consumerism and high-deductible health plan adoption, consumer engagement and risk management.
July 2022
![]() |
Has been acquired by ClaimLogiq
Exclusive financial advisor
SyTrue
Has been acquired by ClaimLogiq
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to SyTrue in its sale to ClaimLogiq, a leading technology enabling payment integrity platform. First Analysis focuses its advisory services on high-growth, entrepreneur-driven software companies like SyTrue and works with management teams to find the best partner to help achieve their objectives.
![](https://www.firstanalysis.com/webfiles/SyTrue_tl_15082022171941.png)
About SyTrue:
SyTrue, the leader in modernizing payer workflows to reduce costs and increase efficiencies, enables healthcare payers to make sense of fragmented, dirty data, driving greater transparency that increases productivity, reduces costs and enhances revenue. Healthcare payers must analyze extensive amounts of unstructured data to identify insights from patients’ episodic health records, which cannot be accessed by traditional methods of search and require expensive chart reviews. SyTrue’s innovative clinical Natural Language Processing (NLP) Operating System NLP OS synthesizes, normalizes and transforms unstructured clinical data into a strategic enterprise-wide digital asset that catalyzes informed decision-making for payment integrity, risk adjustment and care coordination. Developed by clinicians and data scientists with deep healthcare domain expertise, SyTrue’s solutions boost the productivity of review teams and generate higher ROI on clinical and medical chart reviews through greater accuracy, speed, repeatability and scalability. SyTrue has processed more than 10 billion health records, yielding insights that lead to increased efficiencies and improvements in financial performance.
![](https://www.firstanalysis.com/webfiles/ClaimLogiq_bl_15082022171941.png)
About ClaimLogiq:
ClaimLogiq is a healthcare software and technology company that delivers a proactive approach to payment integrity through a powerful, simplified solution. The unique payer-facing, claim-analyzing solution is HITRUST CSF certified and makes claim reviews accessible to all size healthcare payers for in-depth insight and real-time access into the status of every claim at every stage of the audit life cycle for controlled, consistent, accurate, and defensible outcomes. ClaimLogiq’s innovative software stands out by allowing payers control, configurability, and transparency over the entire claim process and can be applied as a SaaS model, full service, or as a hybrid to suit the specific needs of every payer.
November 2021
![]() |
Has been acquired by Sensata Technologies
Exclusive financial advisor
SmartWitness
Has been acquired by Sensata Technologies
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to SmartWitness in its sale to Sensata Technologies (ST). First Analysis focuses its advisory services on high-growth, entrepreneur-driven software companies like SmartWitness. The First Analysis team worked closely with the founder and management team to optimally position the company and find the best partner to help SmartWitness to continue to achieve its objectives. First Analysis was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
![](https://www.firstanalysis.com/webfiles/SmartWitness_tl_08122021122525.png)
About SmartWitness:
SmartWitness is a leading global provider of video telematics solutions with roots dating back to 2007. Ranked as one of the top five providers by industry analysts, the company sells exclusively through integrators and channel partners using its best-in-class platform, SmartAPI. With over 250,000 connected devices deployed and logging 50 million miles per day, SmartWitness provides video telematics hardware, software and services that help partners develop fleet management solutions that optimize operations, improve driving behavior and mitigate risk. Additionally, the FIA European Truck Racing Championship (ETRC) depends on SmartWitness to capture and protect the truth as its official provider of judicial review.
![](https://www.firstanalysis.com/webfiles/Sensata Technologies_HZ_bl_08122021122525.png)
About Sensata Technologies:
Sensata Technologies is a leading industrial technology company that develops sensors, sensor-based solutions, including controllers and software, and other mission-critical products to create valuable business insights for customers and end users. For more than 100 years, Sensata has provided a wide range of customized, sensor-rich solutions that address complex engineering requirements to help customers solve difficult challenges in the automotive, heavy vehicle, off-road, industrial and aerospace industries. With more than 19,000 employees and operations in 13 countries, Sensata’s solutions help to make products safer, cleaner and more efficient, more electrified and more connected.
November 2021
![]() |
Strategic growth investment from Equality Asset Management
Exclusive financial advisor
Miva
Strategic growth investment from Equality Asset Management
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to Miva in securing a significant growth investment from Equality Asset Management. First Analysis focuses its advisory services on high-growth, entrepreneur-driven companies like Miva. The First Analysis team worked closely with the management team to optimally position the company and find the best partner to help Miva to continue to achieve its objectives. First Analysis was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contact, due diligence, and negotiation.
![](https://www.firstanalysis.com/webfiles/Miva_tl_01122021211526.png)
About Miva:
Miva offers a flexible, adaptable and scalable e-commerce platform that enables businesses to drive sales, maximize average order value, cut overhead costs and increase revenue. Miva has been helping businesses realize their potential for over 20 years by empowering retail, wholesale and direct-to-consumer sellers across all industries to transform their business through e-commerce.
![](https://www.firstanalysis.com/webfiles/Equality Asset Mgmt_bl_01122021211526.png)
About Equality Asset Management:
Equality Asset Management is a growth-focused private equity firm. Equality provides equity capital and strategic and operating support to companies with long-term growth potential in the technology and tech-enabled services sectors. With decades of investment experience and operating experience, the firm has earned a reputation for value-creation, serving as steadfast partners to Founders and CEOs. Equality is based in Boston.
August 2021
![]() |
Investment by NexPhase Capital
Exclusive financial advisor
Selerix Systems
Investment by NexPhase Capital
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to Selerix in securing an investment from NexPhase Capital. First Analysis focuses its advisory services on high-growth, entrepreneur-driven companies like Selerix. The First Analysis team worked closely with the management team to optimally position the company and find the best partner to help Selerix to continue to achieve its objectives. First Analysis was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
![](https://www.firstanalysis.com/webfiles/Selerix_simple_tl_26082021071756.png)
About Selerix Systems:
Selerix Systems produces software (Selerix BenSelect and Selerix Engage) used by employers, brokers and carriers to conquer the chaos of benefits administration, employee engagement, and Affordable Care Act (ACA) reporting. The flexibility of the Selerix BenSelect platform accommodates both core and voluntary insurance products with ease. With an active user base of over 8.3 million client employees, Selerix's innovative software solutions are trusted by organizations in a wide variety of industries, including healthcare, education, transportation/logistics, state and local government, nonprofit, high technology and waste management.
![](https://www.firstanalysis.com/webfiles/NexPhase_bl_26082021071756.png)
About NexPhase Capital:
NexPhase Capital is a thematic and operationally-focused private equity firm that invests in lower middle market growth-oriented companies within three distinct sectors: consumer, healthcare and software. The firm targets companies that have reached a growth inflection point and are seeking a value-added partner to help navigate the “next phase.” The NexPhase team has extensive industry and operational experience and NexPhase’s partners have invested together for over a decade. The firm has completed more than 80 investments including add-ons and targets control equity investments between $25 million and $150 million.
August 2021
![]() |
Has been acquired by WellSky
Exclusive financial advisor
Healthify
Has been acquired by WellSky
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to Healthify in its sale to WellSky, a leading health and community care technology company. The First Analysis team worked closely with the management team to optimally position the company and find the best partner to help Healthify to continue to achieve its objectives. First Analysis was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
![](https://www.firstanalysis.com/webfiles/Healthify_tl_03082021094834.png)
About Healthify:
Powered by a mission to build a world where no one's health is hindered by their need, Healthify builds the infrastructure to support social determinants of health (SDoH) initiatives at scale. The company builds and manages accountable networks of community-based organizations and provides the necessary interoperable technology platform to allow the healthcare sector to coordinate care within the network. Healthify works with health plans, providers, and community partners in all fifty states and is dedicated to community partner sustainability and demonstrating ROI for social service interventions to ensure families receive the services they need to thrive.
![](https://www.firstanalysis.com/webfiles/WellSky_bl_03082021094834.png)
About WellSky:
WellSky is a technology company leading the movement for intelligent, coordinated care worldwide. Our next-generation software, analytics, and services power better outcomes and lower costs for stakeholders across the health and community care continuum. In today’s value-based care environment, WellSky helps providers, payers, health systems and community organizations solve tough challenges, improve collaboration for growth, harness the power of data analytics and achieve better outcomes by further connecting clinical and social care. WellSky serves more than 20,000 client sites — including the largest hospital systems, blood banks, cell therapy labs, blood centers, home health and hospice franchises, post-acute providers, government agencies and human services organizations. Informed by more than 40 years of providing software and expertise, WellSky anticipates clients’ needs and innovates relentlessly to ultimately help more people thrive.
July 2021
![]() |
Series A financing co-led by Providence Ventures and Health Enterprise Partners
Exclusive financial advisor
$15,000,000
Kno2
$15,000,000
Series A financing co-led by Providence Ventures and Health Enterprise Partners
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to Kno2 for its $15 million Series A funding round. Kno2 enables interoperability at scale across every patient care setting with the capability to send, receive, find and use patient information with everyone. First Analysis focuses its advisory services on high-growth, entrepreneur-driven companies like Kno2. The First Analysis team worked closely with the management team to optimally position the company and find the best partner to help Kno2 to continue to achieve its growth objectives. First Analysis was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contact, due diligence, and negotiation.
![](https://www.firstanalysis.com/webfiles/Kno2_tl_19072021130333.png)
About Kno2:
Kno2 connects all participants across the care continuum, human or technology, for the secure, effortless, and maximized exchange of patient information. Serving as healthcare’s largest network aggregator, Kno2’s patented API technology provides connectivity and exchange across every major national network, a growing number of regional networks such as HIEs, cloud fax, proprietary platforms that drive critical workflows, and continued expansion of EHR integrations. A technology vendor no longer has to be concerned with the heavy lift of connecting to each network and can stay focused to its core business and application, driving the best user experience possible within their technology. This is what it means to be Kno2 Connected.
May 2021
![]() |
Series B financing led by TT Capital Partners
Exclusive financial advisor
$25,000,000
SymphonyRM
$25,000,000
Series B financing led by TT Capital Partners
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to SymphonyRM for its $25 million Series B funding. The First Analysis team worked closely with the management team to optimally position the company and find the best partner to help SymphonyRM to continue to achieve its growth objectives. First Analysis was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
![](https://www.firstanalysis.com/webfiles/SymphonyRM_tl_18052021101405.png)
About SymphonyRM:
SymphonyRM is helping health systems transform how they acquire, engage, and retain patients by creating an engagement model rivaling the capabilities of world-class, consumer-centered organizations. By generating data-driven, prioritized next best actions for every consumer, prospect and provider in a health system, SymphonyRM is helping organizations anticipate member needs and use proactive outreach to build deeper customer relationships and drive better outcomes while increasing revenue.
![](https://www.firstanalysis.com/webfiles/TripleTree_bl_18052021101727.png)
About TT Capital Partners:
TT Capital Partners (TTCP) is a healthcare investor, collaborating with healthcare technology and services companies that have the potential to become market leaders. Leveraging the insights garnered from a unique knowledge-based platform, TTCP has invested in some of the most innovative, high-growth healthcare businesses. TTCP is part of the TripleTree healthcare merchant bank.
January 2021
![]() |
SwipeSense has been sold to SC Johnson
Exclusive financial advisor
SwipeSense
SwipeSense has been sold to SC Johnson
Exclusive financial advisor
![](https://www.firstanalysis.com/webfiles/SwipeSense2_tl_22012021111405.png)
About SwipeSense:
SwipeSense is a healthcare technology company whose mission is to eliminate harm in hospitals. The company designs and markets an RTLS platform that powers electronic hand hygiene monitoring, real-time asset tracking, and nursing insights applications. SwipeSense is a high-growth venture backed company headquartered in Chicago, Ill.
![](https://www.firstanalysis.com/webfiles/SCJohnson_bl_27082021135119.png)
About SC Johnson:
SC Johnson is a family company dedicated to innovative, high-quality products, excellence in the workplace and a long-term commitment to the environment and the communities in which it operates. Based in the USA, the company is one of the world's leading manufacturers of household cleaning products and products for home storage, air care, pest control and shoe care, as well as professional products. It markets such well-known brands as GLADE®, KIWI®, OFF!®, PLEDGE®, RAID®, SCRUBBING BUBBLES®, SHOUT®, WINDEX® and ZIPLOC® in the U.S. and beyond, with brands marketed outside the U.S. including AUTAN®, BAYGON®, BRISE®, KABIKILLER®, KLEAR®, MR MUSCLE® and RIDSECT®. The 135-year-old company employs approximately 13,000 people globally and sells products in virtually every country around the world.
January 2021
![]() |
First equity investment led by Equality Asset Management
Exclusive financial advisor
PCMI Corporation
First equity investment led by Equality Asset Management
Exclusive financial advisor
First Analysis focuses its advisory services on high-growth, entrepreneur-driven software companies like PCMI. The First Analysis team worked closely with the founder and management team to optimally position the company and find the best partner to help PCMI to continue to achieve its growth objectives. First Analysis was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contract, due diligence and negotiation.
![](https://www.firstanalysis.com/webfiles/PCMI_tl_20012021105412.png)
About PCMI Corporation:
PCMI offers a modular package of software solutions for the administration of finance and insurance products, service contracts and extended warranties. PCMI’s SaaS platform, PCRS (Policy Claim and Reporting Solutions), supports and automates the full lifecycle of all aftermarket products and provides the most flexible environment for administrators, insurers, original equipment manufacturers, agents and dealers to launch new products. Its global team enables continuous around-the-clock innovation and customer-focused support.
![](https://www.firstanalysis.com/webfiles/Equality Asset Mgmt_bl_20012021105715.png)
About Equality Asset Management:
Equality Asset Management is a growth-focused private equity firm. Equality provides equity capital and strategic and operating support to companies with long-term growth potential in the technology and tech-enabled healthcare sectors. With decades of investment experience and operating experience, the firm has earned a reputation for value-creation, serving as steadfast partners to Founders and CEOs. Equality is based in Boston.
January 2021
![]() |
Has been sold to Cedar Gate Technologies
Exclusive financial advisor
Enli Health Intelligence
Has been sold to Cedar Gate Technologies
Exclusive financial advisor
First Analysis focuses its advisory services on high-growth, entrepreneur-driven companies like Enli. The First Analysis team was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contact, due diligence, and negotiation.
![](https://www.firstanalysis.com/webfiles/enli_simple_sm_tl_23012021094011.png)
About Enli Health Intelligence:
Enli, the market leader in population health IT, develops software tools for value-based care analytics and care coordination. Enli has been name Best in KLAS for Population Health Management in 2017, 2018, and 2020. Enli is the first population health management company to measure the financial impact of quality improvement in value-based care contracts, and to supply the analytics-driven care coordination tools necessary to exceed contract measures.
![](https://www.firstanalysis.com/webfiles/Cedar Gate_bl_21012021075736.png)
About Cedar Gate Technologies:
Cedar Gate Technologies is a leading value-based care performance management company founded in 2014 by David B. Snow Jr., a nationally recognized Fortune 50 CEO, in partnership with GTCR, a leading Chicago-based private equity firm. Ascension Ventures, a strategic healthcare venture firm, and Cobalt Ventures, the investment subsidiary of BCBS of Kansas City, have subsequently invested as well.
Cedar Gate provides high-performance analytic, technological administrative and advisory services to providers, payers and self-insured employers to exceed performance thresholds of value-based care contracts, networks and programs. Based in Greenwich, Connecticut, Cedar Gate leverages its deep healthcare expertise and nationally-recognized platform to deliver end-to-end systems and services empowering any healthcare organization, at any point on the value-based care continuum, to excel at value-based care.
December 2020
![]() |
Trialscope has been sold to Informa Pharma Intelligence
Exclusive financial advisor
Trialscope
Trialscope has been sold to Informa Pharma Intelligence
Exclusive financial advisor
First Analysis worked with many strategic and financial parties during the COVID-19 pandemic to drive a rapid outcome that met TrialScope’s financial and strategic goals.
![](https://www.firstanalysis.com/webfiles/TrialScope_tl_22022021105009.png)
About Trialscope:
TrialScope gives your clinical trial data superpowers. The TrialScope Transparency Cloud makes centralizing, structuring and activating clinical trial information simple, for use across the organization and at every stage of the study. Our integrated platform is used by 16 of the top 20 clinical trial sponsors in the world, who rely on TrialScope to ensure disclosure compliance, maximize trial transparency, improve patient engagement and accelerate study recruitment.
![](https://www.firstanalysis.com/webfiles/Informa_PharmaIntelligence_bl_22022021105009.png)
About Informa Pharma Intelligence:
Informa Pharma Intelligence powers a full suite of analysis products - Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet In Vivo and most recently TrialScope – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth. With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers.
June 2020
![]() |
Minority equity investment by Perrigo
Exclusive financial advisor
$50,000,000
Kazmira
$50,000,000
Minority equity investment by Perrigo
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to Kazmira for its $50 million strategic investment by Perrigo Company (PRGO). In collaboration with Perrigo, the investment will be applied to scale up Kazmira’s facilities and laboratories, proactively engage with regulatory authorities, further develop Kazmira’s product portfolio, extend Kazmira’s reach into retail mass markets, and enhance Kazmira’s strong management and technical teams. First Analysis focuses its advisory services on high-growth, entrepreneur-driven companies like Kazmira. The First Analysis team was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contact, due diligence, and negotiation.
![](https://www.firstanalysis.com/webfiles/Kazmira_tl_24082020133524.png)
About Kazmira:
Headquartered in Watkins, Colorado, Kazmira is an industrial scale producer of high purity, THC-free, broad-spectrum CBD oil and THC-free CBD isolate from American-grown ground industrial hemp. The company produces highly concentrated THC-free oils using a proprietary technology platform that enables the supply of products that are free of THC, pesticides, solvent residues and heavy metals. Kazmira has demonstrated an ability to design innovative products and processes that are tailored to meet consumer self-care demands while being well-positioned for success in an evolving regulatory environment. The proprietary technology platform used by Kazmira allows it to separately produce other minor non-psychoactive Cannabinoids present in industrial hemp and in that regard, Kazmira has recently implemented a production line capable of producing CBC in commercial quantities.
![](https://www.firstanalysis.com/webfiles/Perrigo_bl_24082020133524.png)
About Perrigo:
Perrigo Company (PRGO) is dedicated to making lives better by bringing quality, affordable self-care products that consumers trust everywhere they are sold. The company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.
September 2019
![]() |
Minority equity investment led by Flexpoint Ford
Exclusive financial advisor
sticky.io
Minority equity investment led by Flexpoint Ford
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to sticky.io (formerly LimeLight CRM) for its capital financing led by Flexpoint Ford. First Analysis focuses its advisory services on high-growth, entrepreneur-driven software companies like sticky.io. The First Analysis team worked closely with the Company to understand the industry and create a unit-based economic model while positioning the Company optimally in the marketplace. First Analysis was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contact, due diligence, and negotiation.
![](https://www.firstanalysis.com/webfiles/Sticky_io_Limelight_tl_29062020102739.png)
About sticky.io:
Headquartered in San Francisco, sticky.io is a global e-commerce and subscription platform that helps brands build lasting bonds with customers. Consumers today expect authentic and personalized experiences when they interact with brands. Being able to deliver the right message and offer at the right time can mean the difference between loyalty and churn. With 450+ partner integrations and over 10,000 merchant customers processing more than $4.5 billion in transactions annually, sticky.io is the leading billing and customer management solution for direct-to-consumer and subscription eCommerce brands.
![](https://www.firstanalysis.com/webfiles/Flexpoint Ford_bl_30062020100657.png)
About Flexpoint Ford:
Flexpoint Ford is a private equity investment firm with $2.3 billion under management specializing in financial services and healthcare. We believe private equity investing in both financial services and healthcare requires deep industry experience as well as relentless focus on the developments in these specialized and highly regulated industries.
July 2019
![]() |
Series C financing led by Updata Partners
Exclusive financial advisor
$22,000,000
Built In
$22,000,000
Series C financing led by Updata Partners
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to Built In for its $22 million series C financing. Updata Partners led the round, with participation from existing investors including MATH Venture Partners, which led Built In's previous two funding rounds. First Analysis focuses its advisory services on high growth entrepreneur-led technology businesses like Built In. The First Analysis team closely partnered with the Company to help define and achieve its growth investment objectives that included finding the right equity partner. First Analysis was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
![](https://www.firstanalysis.com/webfiles/Built In_tl_12042020150516.png)
About Built In:
Working in tech is a lifestyle. Built In helps people live it with purpose. Across the most vibrant tech hubs in the U.S., the company helps tech professionals stay on top of tech news and trends, expand their networks and carve out futures at companies they believe in. Its market-specific sites serve more than 1,800 customers and an audience of 1 million tech professionals every month. Built In recently launched BuiltIn.com, a national hub for tech trend coverage and resources to help people grow in their careers.
![](https://www.firstanalysis.com/webfiles/Updata Partners_sm_bl_13042020055342.png)
About Updata Partners:
Updata Partners is a leading technology growth equity firm based in Washington, DC. Led by an investment team averaging more than 25 years of technology experience, Updata invests in high-growth software and software-driven businesses where the combination of its capital and operating experience will help accelerate success.
March 2019
![]() |
Follow-on
Co-manager
$397,000,000
Pluralsight
$397,000,000
Follow-on
Co-manager
![](https://www.firstanalysis.com/webfiles/Pluralsght_2_tl_12042020151847.png)
About Pluralsight:
Pluralsight is an enterprise technology skills platform that delivers a unified, end-to-end learning experience for businesses across the globe. Through a subscription service, companies are empowered to move at the speed of technology, increasing proficiency, innovation and efficiency. Founded in 2004 and trusted by Fortune 500 companies, Pluralsight provides members with on-demand access to a digital ecosystem of learning tools, including Pluralsight IQ, directed learning paths, expert-authored courses, interactive labs, and analytics.
March 2019
![]() |
Has been sold to Tabula Rasa Healthcare
Exclusive financial advisor
$150,000,000
PrescribeWellness
$150,000,000
Has been sold to Tabula Rasa Healthcare
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor in the sale of PrescribeWellness, a leading cloud-based patient relationship management solutions company. First Analysis provided advisory expertise to PrescribeWellness throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
![](https://www.firstanalysis.com/webfiles/PrescribeWellness_tl_12042020152338.png)
About PrescribeWellness:
Headquartered in Irvine, CA, PrescribeWellness is a leading cloud-based patient relationship management company that inspires collaboration between pharmacies, payers, providers, pharmaceutical companies, and patients for better health. The company enables cooperation between disparate healthcare systems for better health across America by connecting patients to locally owned community pharmacies. Its proprietary cloud-based platform empowers pharmacists to provide more effective preventive healthcare services, which improve medication adherence, chronic disease management, transitions in care and population health. With data integration and behavioral science as the foundation, PrescribeWellness software solutions position the pharmacist at the center of community healthcare.
![](https://www.firstanalysis.com/webfiles/Tabula Rasa_bl_13042020055710.png)
About Tabula Rasa HealthCare:
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize performance to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications, including EireneRx and MedWise, provide solutions for a range of payers, providers and other healthcare organizations.
March 2019
![]() |
Follow-on
Co-manager
$275,000,000
Benefitfocus
$275,000,000
Follow-on
Co-manager
![](https://www.firstanalysis.com/webfiles/Benefitfocus_blue_tl_12042020152830.png)
About Benefitfocus:
Benefitfocus (NASDAQ: BNFT) unifies the entire U.S. benefits industry on a single technology platform to protect consumers' health, wealth, property and lifestyle. The company's powerful cloud-based software, data-driven insights and thoughtfully designed services, enable employers, insurance brokers, health plans and suppliers to simplify the complexity of benefits administration and deliver a world-class benefits experience.
January 2019
![]() |
Follow-on
Co-manager
$105,000,000
Casella Waste Systems
$105,000,000
Follow-on
Co-manager
![](https://www.firstanalysis.com/webfiles/Casella_2_tl_12042020153544.png)
About Casella Waste Systems:
Casella was founded in 1975 as a single truck operation in Rutland, Vermont. In 1977, Casella opened the first recycling facility in Vermont. The company has remained under the same management for over 40 years. Over time Casella's footprint has grown to include six states. Casella's mission is to create value for its customers, communities, and the company by Giving Resources New Life®. Casella provides resource management expertise and services to residential, commercial, municipal and industrial customers in the areas of solid waste resource collection, recycling, organics, energy recovery and disposal.
January 2019
![]() |
Has been sold to Cardinal Health
Exclusive financial advisor
Mirixa Corp.
Has been sold to Cardinal Health
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor in the sale of Mirixa, a leading healthcare technology and services company specializing in medication therapy management (MTM). First Analysis provided advisory expertise to Mirixa throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
![](https://www.firstanalysis.com/webfiles/Mirixa_sm_tl_12042020154639.png)
About Mirixa Corp.:
Headquartered in Reston, VA, Mirixa was the leading provider of medication therapy management software solutions. The company’s solution and large pharmacy footprint enabled its customers to successfully engage patients, manage chronic conditions, and improve adherence and clinical outcomes while reducing healthcare costs.
Cardinal Health announced that it will integrate the business into OutcomesMTM. The two will combine to offer the highest quality MTM programs for payers and enhance payable service opportunities for MTM providers. Merging MirixaPro and the OutcomesMTM Connect Platform will create efficiencies for pharmacists delivering MTM services to better support them in optimizing medication regimens and reducing medication-related problems for eligible members.
August 2018
![]() |
Minority growth equity investment by Primus
Exclusive financial advisor
$60,000,000
ClearCompany
$60,000,000
Minority growth equity investment by Primus
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to ClearCompany for its $60 million growth capital financing round led by Primus Capital. ClearCompany is the leading recruiting and talent management software solution that helps companies identify, hire and engage more A Players, and the funds will be deployed to support the company’s strong growth and recently expanded partnership with ADP.
![](https://www.firstanalysis.com/webfiles/ClearCompany_tl_13042020060517.png)
About ClearCompany:
For more than a decade, ClearCompany has helped companies identify, hire and engage millions of A Players from nearly 50 million applicants. We designed and built an organic, unified platform to deliver better hiring experiences, seamless onboarding, company-wide goal alignment and performance management, all driven by best practices.
![](https://www.firstanalysis.com/webfiles/Primus Capital_bl_13042020060517.png)
About Primus:
Founded in 1984 and with offices in Cleveland and Atlanta, Primus is a growth-oriented private equity firm focused on investing in leading healthcare, software, and technology-enabled services companies. The company is currently managing Primus Capital Fund VIII, building on a long history of successful investing. Primus has invested in over 130 companies, partnering with exceptional management teams to accelerate growth and create shareholder value by applying industry knowledge, financial resources, and investment experience.
August 2018
![]() |
Follow-on
Co-manager
$143,692,500
NeoGenomics
$143,692,500
Follow-on
Co-manager
![](https://www.firstanalysis.com/webfiles/NeoGenomics_tl_15042020080709.png)
About NeoGenomics :
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP-accredited and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad, Fresno and San Diego California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP-accredited laboratories in Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
July 2018
![]() |
Convertible debt
Financial advisor
$200,000,000
CalAmp Corp.
$200,000,000
Convertible debt
Financial advisor
![](https://www.firstanalysis.com/webfiles/CalAmp_tl_13042020061928.png)
About CalAmp Corp.:
CalAmp (Nasdaq: CAMP) is a global technology solutions pioneer transforming the mobile connected economy. CalAmp helps reinvent business and improve lives around the globe with technology solutions that streamline complex mobile IoT deployments and bring intelligence to the edge. The company's software and subscription-based services, scalable cloud platform and intelligent devices collect and assess business-critical data from mobile assets and their contents. CalAmp calls this The New How, facilitating efficient decision making, optimizing mobile asset utilization and improving road safety. Headquartered in Irvine, California, CalAmp has been publicly traded since 1983 and has 20 million products installed and over 1.3 million software and services subscribers worldwide.
June 2018
![]() |
IPO
Co-manager
$88,200,000
Charah Solutions
$88,200,000
IPO
Co-manager
![](https://www.firstanalysis.com/webfiles/Charah Solutions_tl_13042020062230.png)
About Charah Solutions:
With 30 years of experience, Charah Solutions Inc. is a leading provider of environmental and maintenance services to the power generation industry, with operations in fossil fuel and nuclear power generation sites across the country. Based in Louisville, Kentucky, Charah Solutions assists utilities with all aspects of managing and recycling ash byproducts generated from the combustion of coal in the production of electricity as well as routine power plant maintenance and outage services for the fossil fuel and nuclear power generation industry. The company also designs and implements solutions for ash pond management and closure, landfill construction, fly ash sales, and structural fill projects. Charah Solutions is the partner of choice for solving customers’ most complex environmental challenges, and as an industry leader in quality, safety, and compliance, the xompany is committed to reducing greenhouse gas emissions for a cleaner energy future.
June 2018
![]() |
Growth equity investment by Mainsail Partners
Exclusive financial advisor
$60,000,000
FairWarning
$60,000,000
Growth equity investment by Mainsail Partners
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor for Mainsail Partners’ $60 million growth equity investment in FairWarning, a leader in data protection and governance solutions. First Analysis provided advisory expertise to FairWarning throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
![](https://www.firstanalysis.com/webfiles/FairWarning_sm_tl_13042020063017.png)
About FairWarning:
FairWarning provides software to protect the health, wealth, and personal information for healthcare, financial services and other businesses with the need to protect sensitive data and support compliance requirements. The company's security solutions provide data protection and governance for core applications, including Electronic Health Records (EHRs), Salesforce, Office 365 and hundreds of other applications.
![](https://www.firstanalysis.com/webfiles/Mainsail Partners_hz_bl_13042020063017.png)
About Mainsail Partners:
Mainsail Partners is a San Francisco-based growth equity firm that invests exclusively in fast-growing, bootstrapped software companies. Since 2003, Mainsail has raised over $1.2 billion in capital and has invested in more than 50 growing companies. The company prioritizes investments in enterprise software companies with compelling business models and at least $4 million in recurring revenue. The company's approach to driving value creation is anchored in a dedicated Operations Team that is purpose-built to help founders scale their businesses and accelerate growth. These women and men include former software company operators who leverage real-world experience, well-established best practices, and a true partnership ethos to support management teams.
May 2018
![]() |
IPO
Co-manager
$310,500,000
Pluralsight
$310,500,000
IPO
Co-manager
First Analysis recently acted as co-manager for Pluralsight Inc.'s $311 million initial public offering. Pluralsight is an enterprise technology learning platform that delivers a unified, end-to-end learning experience for businesses across the globe. Through its subscription service, companies are empowered to move at the speed of technology, increasing proficiency, innovation, and efficiency. Founded in 2004 and trusted by Fortune 500 companies, Pluralsight provides its members with on-demand access to a digital ecosystem of learning tools, including adaptive skill tests, directed learning paths, expert-authored courses, interactive labs and live mentoring.
![](https://www.firstanalysis.com/webfiles/Pluralsght_2_tl_13042020063238.png)
About Pluralsight:
Pluralsight is an enterprise technology skills platform that delivers a unified, end-to-end learning experience for businesses across the globe. Through a subscription service, companies are empowered to move at the speed of technology, increasing proficiency, innovation and efficiency. Founded in 2004 and trusted by Fortune 500 companies, Pluralsight provides members with on-demand access to a digital ecosystem of learning tools, including Pluralsight IQ, directed learning paths, expert-authored courses, interactive labs, and analytics.
January 2018
![]() |
Has been sold to Daxko
Exclusive financial advisor
Club Automation
Has been sold to Daxko
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor in the sale of Club Automation, a leading provider of web-based member management software for gyms and health clubs. First Analysis provided advisory expertise to Club Automation throughout the transaction, including preparation, positioning, due diligence and negotiation.
![](https://www.firstanalysis.com/webfiles/ClubAutomation_tl_13042020063753.png)
About Club Automation:
Headquartered in Bannockburn, IL, Club Automation is the leading provider of health club management software. Originally designed as a tennis scheduling tool, the Club Automation solution set has expanded into a comprehensive front desk, CRM, billing, payroll, scheduling, text messaging and reporting solution set. As a result of using the solution, health clubs are better able to grow revenue, reduce costs, and engage both current and potential customers.
![](https://www.firstanalysis.com/webfiles/Daxko_bl_13042020063753.png)
About Daxco:
Daxko delivers comprehensive technology and payment solutions and experienced services to the member-based health and wellness market. Most recently, the company expanded its portfolio to offer digital marketing services and full-service billing to health clubs, boutique fitness studios, campus recreation facilities, integrated wellness centers, YMCAs, and JCCs. Since 1998, Daxko has grown to serve customers spanning 58 countries, 10,000 facilities, and over 20 million members.
January 2018
![]() |
Convertible senior note
Co-manager
$200,000,000
Coupa Software
$200,000,000
Convertible senior note
Co-manager
![](https://www.firstanalysis.com/webfiles/Coupa Software_sm_tl_13042020064251.png)
About Coupa Software:
Coupa Software, based in San Mateo, Calif., provides a unified, cloud-based spend management platform that connects hundreds of organizations representing the Americas, EMEA, and APAC with millions of suppliers globally.
December 2017
![]() |
Follow-on
Co-manager
$82,500,000
Tabula Rasa HealthCare
$82,500,000
Follow-on
Co-manager
![](https://www.firstanalysis.com/webfiles/Tabula Rasa_tl_15042020080935.png)
About Tabula Rasa HealthCare:
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize performance to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications, including EireneRx and MedWise, provide solutions for a range of payers, providers and other healthcare organizations.
September 2017
![]() |
Follow-on
Co-manager
$179,000,000
2U Inc.
$179,000,000
Follow-on
Co-manager
![](https://www.firstanalysis.com/webfiles/2U_tl_13042020064607.png)
About 2U Inc.:
2U, based in Landover, Md., partners with top tier colleges and universities to create online programs. Its cloud-based software-as-a-service platform allows partners to educate and engage students globally.
July 2017
![]() |
Preferred stock growth investment by Bison Capital
Exclusive placement agent
MVTRAC
Preferred stock growth investment by Bison Capital
Exclusive placement agent
![](https://www.firstanalysis.com/webfiles/MVTrac_tl_13042020070010.png)
About MVTRAC:
Home of The Intelligent Data Network, MVTRAC is the leading provider of on-demand LPR data and technology solutions.
![](https://www.firstanalysis.com/webfiles/Bison Capital_bl_13042020070010.png)
About Bison Capital:
Bison Capital invests in leading middle-market businesses that have significant opportunities for value creation and strong, entrepreneurial management teams that are able to capitalize on their long term potential.
May 2017
![]() |
Follow-on
Co-manager
$346,500,000
Advanced Disposal
$346,500,000
Follow-on
Co-manager
![](https://www.firstanalysis.com/webfiles/Advanced Disposal_HZ_tl_13042020070255.png)
About Advanced Disposal:
Advanced Disposal, now part of Waste Management (WM), is the fourth largest non-hazardous solid waste management company in the United States, as measured by revenue. The company provides non-hazardous solid waste collection, transfer, recycling and disposal services for residential, commercial and industrial customers across the Southeast, Midwest and Eastern regions of the United States, as well as in the Commonwealth of the Bahamas.
March 2017
![]() |
Senior secured notes
Financial advisor
$250,000,000
ORBCOMM Inc.
$250,000,000
Senior secured notes
Financial advisor
![](https://www.firstanalysis.com/webfiles/Orbcomm_2_sm_tl_13042020070536.png)
About ORBCOMM Inc. :
ORBCOMM Inc. (ORBC), based in Rochelle Park, N.J., is a provider of global machine-to-machine (M2M) solutions and the only commercial satellite network 100% dedicated to M2M.
December 2016
![]() |
Senior secured notes
Co-manager
$130,000,000
Avison Young
$130,000,000
Senior secured notes
Co-manager
![](https://www.firstanalysis.com/webfiles/Avison Young_tl_13042020070804.png)
About Avison Young:
Avison Young is the world’s fastest-growing commercial real estate services firm. Headquartered in Toronto, Canada, Avison Young is a collaborative, global firm owned and operated by its Principals. Founded in 1978, with legacies dating back more than 200 years, the company comprises approximately 5,000 real estate professionals in 108 offices in 14 countries. The firm’s experts provide value-added, client-centric investment sales, leasing, advisory, management and financing services to clients across the office, retail, industrial, multi-family and hospitality sectors.
Avison Young is a 2019 winner of the Canada's Best Managed Companies Platinum Club designation, having retained its Best Managed designation for eight consecutive years.
November 2016
![]() |
Has acquired GPS Heroes
Exclusive financial advisor
WorkWave
Has acquired GPS Heroes
Exclusive financial advisor
![](https://www.firstanalysis.com/webfiles/WorkWave_tl_13042020071530.png)
About WorkWave:
WorkWave empowers service-oriented companies to reach their full potential through scalable, cloud-based software solutions that support every stage of a business life cycle. We are a trusted partner for thousands of customers across a wide variety of industries, including pest control, lawn care, cleaning, HVAC, plumbing and electrical, and last-mile delivery. WorkWave is unique in that it offers its customers solutions that support the full-service lifecycle, providing businesses with everything from brand awareness and digital marketing to sales, service and the customer experience. Through versatile software solutions, strategic business advice, and a broad network of partners, WorkWave goes beyond just software – we are a partner in enabling our customers to reach their full potential at each stage of their business journey. WorkWave is a division of global enterprise applications provider IFS.
![](https://www.firstanalysis.com/webfiles/GPS Heroes_bl_13042020071530.png)
About GPS Heroes:
GPS Heroes is a leading GPS and telematics company serving small and medium-sized businesses (SMBs).
October 2016
![]() |
IPO
Co-manager
$346,500,000
Advanced Disposal
$346,500,000
IPO
Co-manager
![](https://www.firstanalysis.com/webfiles/Advanced Disposal_HZ_tl_13042020071930.png)
About Advanced Disposal:
Advanced Disposal, now part of Waste Management (WM), is the fourth largest non-hazardous solid waste management company in the United States, as measured by revenue. The company provides non-hazardous solid waste collection, transfer, recycling and disposal services for residential, commercial and industrial customers across the Southeast, Midwest and Eastern regions of the United States, as well as in the Commonwealth of the Bahamas.
September 2016
![]() |
Series B convertible preferred stock by Primus
Exclusive placement agent
Certona
Series B convertible preferred stock by Primus
Exclusive placement agent
First Analysis acted as the exclusive placement agent in an equity investment in Certona, the leader in omnichannel personalization solutions for the world’s largest brands and retailers. First Analysis provided advisory expertise to Certona throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
![](https://www.firstanalysis.com/webfiles/Certona_tl_13042020072434.png)
About Certona:
Headquartered in San Diego, CA, Certona is the leading provider of real-time, personalized content management experience solutions. Certona pioneered the use of patented machine learning and predictive algorithms for real-time profiling of individual shoppers across various digital retail channels. Within 3-4 clicks on a site, the Company’s personalization platform enables retailers to accurately predict the next best action for the shopper to deliver the most relevant, in-the-moment shopping experience. As a result, Certona’s clients experience significant improvements in customer engagement, conversions and sales. Founded in 2004, Certona now serves over 40 billion personalized consumer experiences a month for many of the world’s leading brands and retailers, leveraging data from every consumer engagement point. Certona was acquired by Kibo, a leader in cloud commerce, in 2019. Kibo sold Certona, now known as Monetate, in 2022.
![](https://www.firstanalysis.com/webfiles/Primus Capital_bl_13042020072434.png)
About Primus:
Founded in 1984 and with offices in Cleveland and Atlanta, Primus is a growth-oriented private equity firm focused on investing in leading healthcare, software, and technology-enabled services companies. The company is currently managing Primus Capital Fund VIII, building on a long history of successful investing. Primus has invested in over 130 companies, partnering with exceptional management teams to accelerate growth and create shareholder value by applying industry knowledge, financial resources, and investment experience.
June 2016
![]() |
IPO
Co-manager
$91,000,000
NantHealth
$91,000,000
IPO
Co-manager
![](https://www.firstanalysis.com/webfiles/NantHealth_sm_tl_13042020072809.png)
About NantHealth:
NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payers, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealth’s comprehensive product portfolio combines the latest technology in payer/provider platforms that exchange information in near-real time (NaviNet and Eviti), and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer).
May 2016
![]() |
Series D preferred stock by SSM Partners
Exclusive placement agent
$19,250,000
Apixio
$19,250,000
Series D preferred stock by SSM Partners
Exclusive placement agent
First Analysis acted as the exclusive placement agent in a $19.3 million growth capital raise for Apixio Inc. - a leader in cognitive computing applications to uncover and make accessible the knowledge from clinical data for optimal healthcare decision-making. First Analysis provided advisory expertise to Apixio throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
![](https://www.firstanalysis.com/webfiles/Apixio_sm_tl_13042020073233.png)
About Apixio:
Headquartered in San Mateo, Calif. and powered by its cognitive computing platform, Apixio brings advanced data to healthcare by extracting and analyzing previously trapped unstructured medical record data, giving healthcare payers and providers unprecedented access to groundbreaking insights. The Company’s computing platform is built upon the insights from analyzing more than six million patient charts. Apixio’s HCC Profiler Solution mines medical charts and Medicare-reported chronic condition data to help its customers compute patient risk scores more efficiently and accurately than they could with traditional chart review methods. It also enables more targeted care delivery and helps Medicare set payor and provider payment for patients enrolled in Medicare Advantage (MA), powering more cost-effective, high-quality care.
![](https://www.firstanalysis.com/webfiles/SSM Partners_bl_13042020073233.png)
About SSM Partners:
SSM has been partnering with talented entrepreneurs for more than 20 years. The firm invests in rapidly growing, technology-enabled companies in the software & technology, internet & consumer and heathcare services & IT industries. SSM companies have differentiated and proven business models, large market opportunities, and the ability to generate high returns on invested capital. Starting with a relationship built on trust, SSM offers its entrepreneur-partners a thorough understanding of the growth company lifecycle and a patient approach to building great businesses.
February 2016
![]() |
Growth investment by Bison Capital
Exclusive placement agent
Cartasite
Growth investment by Bison Capital
Exclusive placement agent
First Analysis acted as the exclusive placement agent in a growth capital raise, closed in February 2016, for Cartasite LLC, a leading provider of Industrial Internet of Things ("IoT") solutions for asset and resource-intensive industries. First Analysis provided advisory expertise to Cartasite throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation. The investment will be used to fuel the growth of Cartasite and comes as oil and other commodity prices have placed increasing pressure on producers and servicers to drive efficiency from their employees.
![](https://www.firstanalysis.com/webfiles/Cartasite_tl_13042020081913.png)
About Cartasite:
Headquartered in Denver, CO, Cartasite was formed in 2004 with the goal of delivering practical technology solutions that enhance safety, security, and operating efficiency for energy, mining and other heavy equipment sectors worldwide. With deployments in 31 countries, customers rely on Cartasite's real-time monitoring systems to produce results that streamline operations, save lives, and protect the environment. Cartasite was acquired by Geoforce in 2019.
![](https://www.firstanalysis.com/webfiles/Bison Capital_bl_13042020081913.png)
About Bison Capital:
Bison Capital invests in leading middle-market businesses that have significant opportunities for value creation and strong, entrepreneurial management teams that are able to capitalize on their long term potential.
December 2015
![]() |
Has been sold to Daxko
Exclusive financial advisor
CSI Software
Has been sold to Daxko
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to CSI Software in its sale to Daxko, a portfolio company of Pamlico Capital.
![](https://www.firstanalysis.com/webfiles/CSI Software_tl_13042020082633.png)
About CSI Software:
Founded in Houston, Texas, in 1977, CSI has long been at the forefront of the club management software industry, helping to introduce computers into the operations of gyms and health clubs. CSI’s SaaS platform is an integrated solution that offers modules to manage every aspect of club management, including accounting, member management, registration/scheduling, reports and analytics, and online services to maximize engagement.
![](https://www.firstanalysis.com/webfiles/Daxko_bl_13042020082633.png)
About Daxco:
Daxko delivers comprehensive technology and payment solutions and experienced services to the member-based health and wellness market. Most recently, the company expanded its portfolio to offer digital marketing services and full-service billing to health clubs, boutique fitness studios, campus recreation facilities, integrated wellness centers, YMCAs, and JCCs. Since 1998, Daxko has grown to serve customers spanning 58 countries, 10,000 facilities, and over 20 million members.
September 2015
![]() |
Follow-on
Co-manager
$105,400,000
Paylocity Holdings Corp.
$105,400,000
Follow-on
Co-manager
![](https://www.firstanalysis.com/webfiles/Paylocity_sm_tl_13042020082908.png)
About Paylocity Holdings Corp.:
Paylocity (PCTY), based in Arlington Heights, Ill., provides cloud-based payroll and human resource solutions to thousands of businesses nationwide.
September 2015
![]() |
Follow-on
Co-manager
$119,000,000
2U Inc.
$119,000,000
Follow-on
Co-manager
![](https://www.firstanalysis.com/webfiles/2U_tl_13042020092240.png)
About 2U Inc.:
2U, based in Landover, Md., partners with top tier colleges and universities to create online programs. Its cloud-based software-as-a-service platform allows partners to educate and engage students globally.
June 2015
![]() |
Convertible senior note
Co-manager
$230,000,000
Proofpoint Inc.
$230,000,000
Convertible senior note
Co-manager
![](https://www.firstanalysis.com/webfiles/Proofpoint_tl_13042020092549.png)
About Proofpoint Inc.:
Proofpoint Inc. (PFPT) provides threat protection, regulatory compliance, archiving and governance, and secure communication solutions worldwide.
May 2015
![]() |
Convertible senior note
Co-manager
$150,000,000
Interactive Intelligence
$150,000,000
Convertible senior note
Co-manager
![](https://www.firstanalysis.com/webfiles/Interactive Intelligence_sm_tl_13042020093111.png)
About Interactive Intelligence:
Interactive Intelligence was a telecommunications software and cloud computing development company that provided unified business communications solutions for call centers, Voice over IP companies, and business process automation. Interactive Intelligence was acquired by Genesys in 2016.
May 2015
![]() |
Follow-on
Co-manager
$87,000,000
HealthStream
$87,000,000
Follow-on
Co-manager
![](https://www.firstanalysis.com/webfiles/HealthStream_tl_13042020093408.png)
About HealthStream:
HealthStream (HSTM) is dedicated to improving patient outcomes through the development of healthcare organizations’ greatest asset: their people. The company's unified suite of solutions is contracted by healthcare organizations across the U.S. for workforce development, training & learning management, talent management, credentialing, privileging, provider enrollment, performance assessment, and managing simulation-based education programs. Based in Nashville, Tennessee, HealthStream has additional offices in Jericho, New York; Boulder; Colorado; Denver, Colorado; San Diego, California; and Chicago, Illinois.
May 2015
![]() |
Has been sold to ProPharma Group
Exclusive financial advisor
Prosar
Has been sold to ProPharma Group
Exclusive financial advisor
![](https://www.firstanalysis.com/webfiles/Prosar_tl_13042020100256.png)
About Prosar:
PROSAR provided pharmacovigilance, safety surveillance, and medical information services to manufacturers of pharmaceuticals, biologics and medical devices. Manufacturers of such products have a regulatory requirement to perform safety surveillance and document adverse events regarding their products and report them to the FDA. The FDA requires manufacturers to meet comprehensive specifications -- including specifications for healthcare staff credentials, standard operating procedures, IT infrastructure, and quality processes - for pharmacovigilance and the provision of medical information. The FDA regularly audits manufacturers for compliance with the regulations and specifications. Outsourcing pharmacovigilance and medical information functions allows pharmaceutical, biotech and device companies to comply with FDA regulations for safety surveillance while greatly reducing costs associated with hiring in-house physicians, pharmacists, and nurses as well as the costs of IT and other in
![](https://www.firstanalysis.com/webfiles/ProPharma_sm_bl_13042020100256.png)
About ProPharma Group:
ProPharma Group, a portfolio company of Linden Capital Partners, is an international, independent, single-source provider of comprehensive compliance services that span the entire lifecycle of pharmaceuticals, biologics, and medical devices. ProPharma Group has more than 1,100 colleagues worldwide providing an unmatched variety of compliance-related services including life science consulting, medical information, pharmacovigilance, and regulatory affairs.
May 2015
![]() |
Convertible senior note
Financial advisor
$150,000,000
CalAmp Corp.
$150,000,000
Convertible senior note
Financial advisor
![](https://www.firstanalysis.com/webfiles/CalAmp_tl_13042020100433.png)
About CalAmp Corp.:
CalAmp Corp. (CAMP), based in Oxnard, Calif., develops wireless communications solutions that deliver data, voice, and video for critical networked communications and other applications.
November 2014
![]() |
Growth investment by Francisco Partners
Exclusive financial advisor
CoverMyMeds
Growth investment by Francisco Partners
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to CoverMyMeds in its growth investment by Francisco Partners, one of the country's pre-eminent technology investors.
![](https://www.firstanalysis.com/webfiles/CoverMyMeds_tl_13042020101715.png)
About CoverMyMeds:
CoverMyMeds is a leader in the medication benefit process and one of the fastest-growing healthcare information technology companies in the US. We help physicians, pharmacists, and their staff complete medication approval requests for any drug and all plans. The Company's technology integrates with payers, EHRs and pharmacy systems to create an efficient electronic process for all participants.
![](https://www.firstanalysis.com/webfiles/Francisco Partners_hz_sm_bl_13042020101715.png)
About Francisco Partners:
Francisco Partners is a leading global private equity firm that specializes in investments in technology and technology-enabled businesses. Since its launch 20 years ago, Francisco Partners has raised over $14 billion in committed capital and invested in more than 275 technology companies, making it one of the most active and longstanding investors in the technology industry. The firm invests in opportunities where its deep sectoral knowledge and operational expertise can help companies realize their full potential.
June 2014
![]() |
Series D preferred stock
Exclusive financial advisor
Putney
Series D preferred stock
Exclusive financial advisor
![](https://www.firstanalysis.com/webfiles/Putney_tl_13042020102517.png)
About Putney:
Putney was a pharmaceutical company committed to providing high quality, cost-effective generic medicines for pets. Putney's reliable supply of affordable drug options empowered veterinarians, allowing them to provide the best possible medicine at the best possible price, and supported pet owners, helping them afford to comply with veterinary recommendations. Putney's investment in research and development focused on creating the next generation of generic veterinary products based on inputs from companion animal veterinarians and its industry partners. Putney was acquired by Dechra Veterinary Products in 2016.
April 2014
![]() |
Series C preferred stock growth investment by Bain Capital
Exclusive placement agent
$13,500,000
Apixio
$13,500,000
Series C preferred stock growth investment by Bain Capital
Exclusive placement agent
First Analysis acted as the exclusive placement agent in a $13.5 million growth capital raise, closed in April 2014, for Apixio Inc. - a leading provider of big data solutions for healthcare analytics. First Analysis provided advisory expertise to Apixio throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
![](https://www.firstanalysis.com/webfiles/Apixio_tl_13042020104119.png)
About Apixio:
Headquartered in San Mateo, Calif. and powered by its cognitive computing platform, Apixio brings advanced data to healthcare by extracting and analyzing previously trapped unstructured medical record data, giving healthcare payers and providers unprecedented access to groundbreaking insights. The Company’s computing platform is built upon the insights from analyzing more than six million patient charts. Apixio’s HCC Profiler Solution mines medical charts and Medicare-reported chronic condition data to help its customers compute patient risk scores more efficiently and accurately than they could with traditional chart review methods. It also enables more targeted care delivery and helps Medicare set payor and provider payment for patients enrolled in Medicare Advantage (MA), powering more cost-effective, high-quality care.
![](https://www.firstanalysis.com/webfiles/Bain Capital Ventures_sm_bl_13042020104119.png)
About Bain Capital Ventures:
Bain Capital Ventures partners with disruptive founders to accelerate their ideas to market. The firm invests from seed to growth in enterprise software, infrastructure software, and industries being transformed by data. Bain Capital Ventures has helped launch and commercialize 200-plus companies since 2000, including investments in DocuSign, Jet.com, Kiva Systems, LinkedIn, Rapid7, SurveyMonkey, Taleo, and TellApart. Bain Capital Ventures has approximately $3.6 billion of assets under management with offices in San Francisco, New York, and Boston.
January 2014
![]() |
Has been sold to ServiceSource
Exclusive financial advisor
$32,500,000
Scout Analytics
$32,500,000
Has been sold to ServiceSource
Exclusive financial advisor
First Analysis acted as the exclusive financial advisor to Scout Analytics and worked closely with the Company's management team throughout the sale process. This included providing advisory expertise and managing the preparatory, buyer coordination and contact, due diligence and final negotiation phases of the transaction.
![](https://www.firstanalysis.com/webfiles/Scout Analytics_sm_tl_13042020105625.png)
About Scout Analytics:
Headquartered in Issaquah, Washington, Scout Analytics was the leading SaaS provider of repeat and recurring revenue optimization, enabling any company to evaluate customer usage data and derive actionable pricing, engagement and upsell opportunities that increase profitability and minimize customer churn. The Scout platform employed a patented usage data platform that correlates revenue streams with user behavior to increase the lifetime value of the user. The company's solutions combined behavioral analytics, data integration and expert revenue advisor support to identify untapped sources of subscription and transaction revenue.
![](https://www.firstanalysis.com/webfiles/Service Source_bl_13042020105626.png)
About ServiceSource:
ServiceSource International brings the world’s greatest brands closer to their customers through digitally-enabled solutions and data-driven insights that personalize and power the “moments that matter”. Backed by 20 years of experience, an industry-leading technology platform, a robust global footprint and a powerful suite of solutions that enhance every touchpoint along the Customer Journey Experience (CJX), ServiceSource delivers impactful revenue growth for global market leaders. Operating out of eight countries with more than 3,000 sales delivery professionals speaking 45 languages, ServiceSource drives billions of dollars in client value annually. ServiceSource is now part of Concentrix (CNXC).
December 2013
![]() |
Convertible senior note
Co-manager
$175,000,000
Proofpoint Inc.
$175,000,000
Convertible senior note
Co-manager
![](https://www.firstanalysis.com/webfiles/Proofpoint_tl_13042020111624.png)
About Proofpoint Inc.:
Proofpoint Inc. (PFPT) provides threat protection, regulatory compliance, archiving and governance, and secure communication solutions worldwide.
November 2013
![]() |
Follow-on
Joint book running manager
$22,500,000
Streamline Health
$22,500,000
Follow-on
Joint book running manager
![](https://www.firstanalysis.com/webfiles/StreamlineHealth_tl_15042020083154.png)
About Streamline Health:
Streamline Health Solutions (STRM) is a healthcare industry leader in capturing, aggregating, and translating enterprise data into knowledge - producing actionable insights that support revenue cycle optimization for healthcare enterprises. Streamline delivers integrated solutions, technology-enabled services and analytics that empower providers to drive revenue integrity in a value-based world. Streamline shares a common calling and commitment to advance the quality of life and the quality of healthcare - for society, our clients, the communities they serve, and the individual patient.
November 2013
![]() |
Registered direct
Co-placement agent
$20,000,000
Athersys Inc.
$20,000,000
Registered direct
Co-placement agent
![](https://www.firstanalysis.com/webfiles/Athersys_sm_tl_13042020120653.png)
About Athersys Inc.:
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company is developing its MultiStem cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization.
November 2013
![]() |
Follow-on
Co-manager
$188,700,000
Demandware
$188,700,000
Follow-on
Co-manager
![](https://www.firstanalysis.com/webfiles/DemandWare_tl_13042020121214.png)
About Demandware:
Demandware Inc., based in Burlington, Mass., was a software-as-a-service e-commerce platform provider that enabled companies to design, implement, and manage their own customized e-commerce sites. Demandware was acquired by Salesforce in 2016.
November 2013
![]() |
Follow-on
Co-manager
$47,000,000
Mazor Robotics
$47,000,000
Follow-on
Co-manager
![](https://www.firstanalysis.com/webfiles/Mazor Robotics_tl_13042020121615.png)
About Mazor Robotics:
Mazor Robotics developed, produced, and marketed medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the United States, Europe, and Asia. Mazor Robotics was acquired by Medtronics in 2018.
February 2013
![]() |
Follow-on
Co-manager
$48,000,000
CalAmp Corp.
$48,000,000
Follow-on
Co-manager
![](https://www.firstanalysis.com/webfiles/CalAmp_tl_13042020121755.png)
About CalAmp Corp.:
CalAmp (Nasdaq: CAMP) is a global technology solutions pioneer transforming the mobile connected economy. CalAmp helps reinvent business and improve lives around the globe with technology solutions that streamline complex mobile IoT deployments and bring intelligence to the edge. The company's software and subscription-based services, scalable cloud platform and intelligent devices collect and assess business-critical data from mobile assets and their contents. CalAmp calls this The New How, facilitating efficient decision making, optimizing mobile asset utilization and improving road safety. Headquartered in Irvine, California, CalAmp has been publicly traded since 1983 and has 20 million products installed and over 1.3 million software and services subscribers worldwide.
January 2013
![]() |
PIPE
Co-lead placement agent
$11,000,000
MRI Interventions
$11,000,000
PIPE
Co-lead placement agent
First Analysis acted as the co-lead placement agent in an $11 million private placement for MRI Interventions, a commercial-stage medical device company enabling a range of minimally invasive procedures in the brain. As part of this investment, the company issued common stock and warrants to purchase common stock.
![](https://www.firstanalysis.com/webfiles/MRIC_tl_13042020122838.png)
About MRI Interventions:
MRI Interventions (MRIC) is a leading platform neurosurgery company. The company’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the company’s current product portfolio include deep-brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics and gene therapy to the brain.
MRI Interventions changed its corporate name to ClearPoint Neuro (CLPT) in February 2020.
January 2013
![]() |
Has been sold to Ascensus
Financial co-advisor
ExpertPlan
Has been sold to Ascensus
Financial co-advisor
![](https://www.firstanalysis.com/webfiles/ExpertPlan_sm_tl_13042020123146.png)
About ExpertPlan:
ExpertPlan Inc. was a leader in providing private-label retirement solutions to the financial services industry. The company's Web-based 401(k) platform enabled ExpertPlan's clients in the financial services industry to service small companies in a more cost-effective and user-friendly manner and provide a broader array of product choices. ExpertPlan built a network of leading asset management firms, third-party administrators, brokers, investment advisers, banks, and insurance companies that used the company's solution to address the small business market. ExpertPlan was acquired by Ascensus in 2013.
![](https://www.firstanalysis.com/webfiles/Ascensus_bl_15042020083029.png)
About Ascensus:
Ascensus helps millions of people save for what matters—retirement, education, and healthcare. Our technology, market insights, and business knowledge enhance the growth and success of our partners, their clients, and savers. Ascensus is the largest independent recordkeeping services provider, third-party administrator, and government savings facilitator in the United States.
October 2012
![]() |
Follow-on
Co-manager
$20,000,000
Athersys Inc.
$20,000,000
Follow-on
Co-manager
![](https://www.firstanalysis.com/webfiles/Athersys_sm_tl_17042020122252.png)
About Athersys Inc.:
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company is developing its MultiStem cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization.
September 2012
![]() |
IPO
Co-manager
$91,000,000
Qualys
$91,000,000
IPO
Co-manager
![](https://www.firstanalysis.com/webfiles/Qualys_tl_18042020141144.png)
About Qualys :
Qualys (QLYS) is a pioneer and leading provider of cloud-based security and compliance solutions with over 15,700 active customers in more than 130 countries, including a majority of each of the Forbes Global 100 and Fortune 100. Qualys helps organizations streamline and consolidate their security and compliance solutions in a single platform and build security into digital transformation initiatives for greater agility, better business outcomes, and substantial cost savings.
August 2012
![]() |
PIPE
Exclusive placement agent
$12,000,000
Streamline Health
$12,000,000
PIPE
Exclusive placement agent
![](https://www.firstanalysis.com/webfiles/StreamlineHealth_tl_17042020135459.png)
About Streamline Health:
Streamline Health Solutions (STRM) is a healthcare industry leader in capturing, aggregating, and translating enterprise data into knowledge - producing actionable insights that support revenue cycle optimization for healthcare enterprises. Streamline delivers integrated solutions, technology-enabled services and analytics that empower providers to drive revenue integrity in a value-based world. Streamline shares a common calling and commitment to advance the quality of life and the quality of healthcare - for society, our clients, the communities they serve, and the individual patient.
August 2012
![]() |
has sold its business and technology assets
Exclusive financial advisor
DRC Inc.
has sold its business and technology assets
Exclusive financial advisor
![](https://www.firstanalysis.com/webfiles/DRC_tl_17042020135309.png)
About DRC Inc.:
April 2012
![]() |
IPO
Co-manager
$33,300,000
Acquity Group
$33,300,000
IPO
Co-manager
![](https://www.firstanalysis.com/webfiles/Acquity Group_Hz_tl_18042020141241.png)
About Acquity Group:
Acquity Group Ltd. was the second-largest independent digital marketing company in the United States, which provided strategy, digital marketing and technical services to help companies enhance their brand experiences and eCommerce performance. Acquity Group was acquired by Accenture (ACN) in 2013.
April 2012
![]() |
IPO
Co-manager
$82,300,000
Proofpoint Inc.
$82,300,000
IPO
Co-manager
![](https://www.firstanalysis.com/webfiles/Proofpoint_tl_17042020134233.png)
About Proofpoint Inc.:
Proofpoint Inc. (PFPT) provides threat protection, regulatory compliance, archiving and governance, and secure communication solutions worldwide.
March 2012
![]() |
PIPE
Exclusive placement agent
$7,200,000
Scientific Learning
$7,200,000
PIPE
Exclusive placement agent
![](https://www.firstanalysis.com/webfiles/ScientificLearning_tl_17042020134113.png)
About Scientific Learning:
Scientific Learning accelerates learning by applying proven research on how the brain learns. Scientific Learning's results are demonstrated in over 270 research studies and protected by over 55 patents. Learners can realize achievement gains of up to two years in as little as three months and maintain an accelerated rate of learning even after the programs end.
Today, more than 2.7 million learners have used Scientific Learning' Fast ForWord and Reading Assistant software products. Scientific Learning provides its offerings directly to parents, K-12 schools and learning centers, and in more than 45 countries around the world.
March 2012
![]() |
IPO
Co-manager
$88,000,000
Demandware
$88,000,000
IPO
Co-manager
![](https://www.firstanalysis.com/webfiles/DemandWare_tl_18042020141321.png)
About Demandware:
Demandware Inc., based in Burlington, Mass., was a software-as-a-service e-commerce platform provider that enabled companies to design, implement, and manage their own customized e-commerce sites. Demandware was acquired by Salesforce in 2016.
March 2012
![]() |
PIPE
Co-placement agent
$9,000,000
Athersys Inc.
$9,000,000
PIPE
Co-placement agent
![](https://www.firstanalysis.com/webfiles/Athersys_sm_tl_17042020133253.png)
About Athersys Inc.:
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company is developing its MultiStem cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization.
January 2012
![]() |
Has acquired Environmental Systems Products
Exclusive financial advisor
$9,700,000
Systech International
$9,700,000
Has acquired Environmental Systems Products
Exclusive financial advisor
![](https://www.firstanalysis.com/webfiles/Systech_sm_tl_17042020132942.png)
About Systech International:
Systech International, established in 1999, is part of the Opus Group and provides turnkey vehicle inspection program management contract services to various levels of government agencies (federal, state and regional) and to individual inspection stations. Opus' share is listed on First North (Stockholm Stock Exchange) under the ticker OPUS.
December 2011
![]() |
Has acquired FAS Controls Inc.
Exclusive financial advisor
Kendrion
Has acquired FAS Controls Inc.
Exclusive financial advisor
![](https://www.firstanalysis.com/webfiles/Kendrion_sm_tl_17042020131923.png)
About Kendrion:
Kendrion develops, manufactures and markets high-quality electromagnetic systems and components for industrial and automotive applications. For more than a century, Kendrion has been engineering precision parts for the world's leading innovators in passenger cars, commercial vehicles and industrial applications. As a leading technology pioneer, Kendrion invents, designs and manufactures complex components and customized systems as well as local solutions on demand. Rooted in Germany, headquartered in the Netherlands and listed on the Amsterdam stock exchange, Kendrion's expertise extends across Europe, to the Americas and Asia. Created with passion and engineered with precision.
![](https://www.firstanalysis.com/webfiles/FAS Controls_bl_17042020131923.jpg)
About FAS Controls Inc.:
FAS Controls designed, developed, and manufactured valves, switches, actuating devices, lights, and control components.
December 2011
![]() |
IPO
Co-manager
$88,000,000
MELA Sciences Inc.
$88,000,000
IPO
Co-manager
![](https://www.firstanalysis.com/webfiles/MELA_tl_17042020130353.png)
About MELA Sciences Inc.:
MELA Sciences is a medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations. The company rebranded and changed its name to Strata Skin Sciences in 2015.
December 2011
![]() |
Series B preferred stock
Exclusive placement agent and financial advisor
$2,050,000
CSA Medical
$2,050,000
Series B preferred stock
Exclusive placement agent and financial advisor
![](https://www.firstanalysis.com/webfiles/CSA Medical_tl_17042020130027.png)
About CSA Medical:
CSA Medical develops and manufactures a proprietary interventional spray cryotherapy technology platform utilizing unique properties of liquid nitrogen spray delivered by a software-driven device with specialty catheters that enable the delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing. The RejuvenAir System is now approved in the EU and under clinical investigation in the United States.
September 2011
![]() |
Series C preferred stock
Exclusive financial advisor
$21,000,000
Putney
$21,000,000
Series C preferred stock
Exclusive financial advisor
![](https://www.firstanalysis.com/webfiles/Putney_tl_17042020125520.png)
About Putney:
Putney was a pharmaceutical company committed to providing high quality, cost-effective generic medicines for pets. Putney's reliable supply of affordable drug options empowered veterinarians, allowing them to provide the best possible medicine at the best possible price, and supported pet owners, helping them afford to comply with veterinary recommendations. Putney's investment in research and development focused on creating the next generation of generic veterinary products based on inputs from companion animal veterinarians and its industry partners. Putney was acquired by Dechra Veterinary Products in 2016.
September 2011
![]() |
Has acquired Integrated Revenue Management
Exclusive financial advisor
Analytix On Demand
Has acquired Integrated Revenue Management
Exclusive financial advisor
![](https://www.firstanalysis.com/webfiles/AOD_tl_18042020141358.png)
About Analytix On Demand:
Analytix On Demand was a provider of SaaS business intelligence solutions for healthcare. As part of the acquisition of Integrated Revenue Management, Analytix On Demand was renamed CentraMed which offers healthcare business intelligence and consulting to hospitals, physicians, and payers.
March 2011
![]() |
Has been sold to Falck Holdings A/S
Financial advisor
Lifestar Response
Has been sold to Falck Holdings A/S
Financial advisor
![](https://www.firstanalysis.com/webfiles/LifeStar_tl_17042020124426.png)
About Lifestar Response:
LifeStar Response Corporation was established as a family-owned ambulance service located on Long Island, New York. In 1996 the company was acquired and combined with three additional Long Island area ambulance services. Two years later the company acquired services located in Northern New Jersey, Maryland and Washington DC. In 1999 Care Ambulance of Alabama, a regional provider established in 1992, joined the LifeStar portfolio. LifeStar Response acquired the operations of AmeriCare Ambulance in 2007, Best American Ambulance in 2009 and LifeStar Ambulance in 2010.
In April of 2011 LifeStar Response Corporation was acquired by Falck, a Denmark based organization, established in 1906 providing ambulance and medical support services in Europe and the United States. Falck is the largest provider of ambulance services in Europe serving 31 countries. LifeStar Response Corporation is licensed to provide ambulance and wheelchair transportation services in nine states. The company is contract
![](https://www.firstanalysis.com/webfiles/Falck Holdings_bl_17042020124426.png)
About Falck Holdings A/S:
Falck Healthcare provides healthcare programs covering more than 3 million people in Sweden, Denmark and Norway and provides more than 1 million muscular and psychological treatments per year.
Falck Healthcare’s customers are insurance companies, pension funds and private businesses providing healthcare programs to their customers and employees. Its services include consultancy, visitation and guidance in call centers as well as physiological and psychological treatments. Through its employee healthcare programs, Falck Healthcare helps reduce costs related to sickness-related absence and incapacity for work.
January 2011
![]() |
Registered direct
Co-lead placement agent
$13,100,000
Athersys Inc.
$13,100,000
Registered direct
Co-lead placement agent
![](https://www.firstanalysis.com/webfiles/Athersys_sm_tl_17042020122450.png)
About Athersys Inc.:
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company is developing its MultiStem cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization.
October 2010
![]() |
Raised capital from Abraxis BioScience
Financial advisor
Ideal Life
Raised capital from Abraxis BioScience
Financial advisor
![](https://www.firstanalysis.com/webfiles/Ideal Life_tl_17042020123151.png)
About Ideal Life:
Ideal Life was a pioneering remote patient monitoring service with 20 years of experience managing collectively over 100,000 monitored patients. Ideal Life was acquired by Raziel Health in March 2020.
![](https://www.firstanalysis.com/webfiles/Abraxis logo_bl_17042020123151.jpg)
About Abraxis BioScience:
Abraxis BioScience was a global biopharmaceutical company that developed treatments for critically ill patients. It had over 2000 employees worldwide in 2007. Abraxis's portfolio included the world's first protein-based nanoparticle chemotherapeutic compound, called nab Technology. The company developed Abraxane, a treatment for metastatic breast cancer. In 2010, Abraxis BioScience was acquired by Celgene Corporation.